



Dedicated To Life

July 27, 2023

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 27, 2023 titled **"Zydus receives final approval from the USFDA for Plerixafor Injection USP, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial"**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives final approval from the USFDA for Plerixafor Injection USP, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial

Ahmedabad, India, 27 July, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial (USRLD: Mozobil[®] Injection, 24 mg/1.2 mL [20 mg/mL]).

Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. The drug will be manufactured at the group's injectable manufacturing facility of Zydus Lifesciences Ltd. (Alidac) at SEZ, Ahmedabad (India).

Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial had annual sales of USD 210 mn in the United States (IQVIA MAT May 2023).

The group now has 374 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2023)

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878